Why 4DMedical stock is suddenly soaring—and how FDA approval could open a billion-dollar market

Shares of 4DMedical Limited (ASX:4DX) surged 35.09% to AUD 0.77 on September 1, 2025, in response to a transformational regulatory milestone. The Australian medical imaging innovator confirmed it had received U.S. FDA 510(k) clearance for its flagship CT:VQ platform—a non-contrast, CT-based lung imaging modality that provides quantitative ventilation and perfusion data without the use of radioactive tracers.

This makes 4DMedical the first company globally to secure regulatory approval for a fully non-invasive, CT-based VQ (ventilation-perfusion) solution, creating a new frontier in respiratory diagnostics. With more than 1 million nuclear VQ scans performed annually in the U.S., the immediate addressable market is pegged at over USD $1.1 billion, with the company eyeing complete disruption of incumbent nuclear medicine modalities.

How does CT:VQ disrupt the current standard of lung imaging—and why are hospitals excited?

CT:VQ eliminates several bottlenecks in conventional nuclear VQ imaging, such as long scan durations, dual-radiotracer handling, and limited access to nuclear infrastructure. Instead, the software overlays advanced motion and density analysis onto routine CT scans—no additional equipment required. This means hospital networks can deploy 4DMedical’s platform across an estimated 14,500 installed CT scanners in the U.S. healthcare system without retrofitting or added training.

The technology’s ability to plug into standard imaging workflows offers clear appeal to radiologists, pulmonologists, and hospital administrators. It also enhances accessibility in rural or underserved areas that lack nuclear medicine capacity—a major point of differentiation in the U.S. market where reimbursement for VQ scans averages USD $1,150.

In terms of validation, CT:VQ demonstrated head-to-head diagnostic parity with SPECT imaging, the current nuclear gold standard. Real-world cases and expert physician panels rated it as equivalent or superior in clarity, resolution, and operational simplicity.

What do the FY2025 results reveal about 4DMedical’s business traction and SaaS scalability?

Beyond regulatory momentum, 4DMedical’s FY2025 full-year results show strong operational and commercial scaling. Operating revenue rose 56% to AUD $5.9 million, primarily driven by a 95% year-on-year increase in SaaS revenue. Gross margins remain above 90%, reinforcing the leverage inherent in its software-driven model.

Scan volumes also posted robust growth, with over 194,000 functional and structural lung scans performed in FY2025. In Q4 alone, the company delivered 74,000 scans across 388 sites globally, representing a 35% QoQ and 105% YoY increase. Notably, the uptick was attributed to high-demand products like LDAi, SeleCT, IQ-UIP, and LVAS.

The company’s cost base showed tightening as well. A Q3-initiated cost-reduction program resulted in AUD $6.5 million in annualised savings, with total receipts from customers up 87% YoY. The company’s proforma cash balance as of June 30, 2025, stood at AUD $16.9 million, with an additional AUD $6.0 million R&D tax credit expected.

How critical is the Philips partnership in the U.S. government healthcare landscape?

Another bullish trigger in 4DMedical’s FY2025 narrative is its deepening strategic alignment with Philips, cemented through a five-year reseller agreement. As of Q3 FY2025, over 200 Philips sales representatives were trained to promote 4DMedical’s software suite—including XV Technology and CT:VQ—to commercial and government clients in the U.S.

Under the deal, Philips holds exclusive distribution rights for U.S. government entities such as the Department of Veterans Affairs (VA) and Department of Defense (DoD). These institutions currently use Philips infrastructure in roughly 50% of VA clinics, giving 4DMedical an inside track to a vast and high-need market for veteran respiratory care.

Jeff DiLullo, Philips’ North America CEO, even highlighted CT:VQ during U.S. Congressional testimony as a textbook example of healthcare modernization, underlining its potential to reduce invasive procedures and enhance access to care for veterans.

What are the next commercial catalysts for 4DMedical’s CT:VQ rollout and beyond?

Following FDA clearance, the focus now shifts to execution. The company has already secured research contracts for CT:VQ with Stanford University and the U.S. Department of Defense’s Brooke Army Medical Center. Clinical presentations at the 2025 ATS conference further cemented its peer credibility.

Looking ahead to FY2026, the company plans to deepen its U.S. penetration across Academic Medical Centers and extend commercial deployments into broader population screening applications, especially with partners like Philips and distribution networks including Olympus, Aidoc, and Nuance.

4DMedical’s CTO and founder Andreas Fouras called this a “defining milestone” not just for the company but for the standard of care in pulmonary imaging. With a strong cash runway, rising scan volumes, and a scalable SaaS model, 4DMedical now appears poised to deliver both top-line growth and category leadership.

Why the market may be starting to price in long-term platform value for 4DMedical

The 35% intraday share price jump in 4DMedical Limited (ASX:4DX) is more than just a knee-jerk reaction to FDA approval news—it reflects a deeper market re-evaluation of the company’s trajectory. After years of operating as a clinical-stage imaging innovator with a pipeline of patented respiratory diagnostics, 4DMedical is now making the leap to a revenue-generating, commercially scaled software-as-a-service (SaaS) platform. With CT:VQ gaining regulatory clearance, the company now has a high-margin, globally deployable imaging solution with validated clinical impact and a capital-light delivery model.

This evolution from a research-heavy R&D profile to a commercial-stage medtech disruptor is exactly the kind of transition that attracts long-only funds, growth managers, and specialist healthcare investors seeking scalable platforms with proven technology. CT:VQ™ not only expands the company’s addressable market into the USD $1.1 billion U.S. VQ scan segment—it also unlocks downstream value via deeper integration with clinical workflows, cross-selling opportunities across its structural-functional scan suite, and future upgrades leveraging its AI engine from the Imbio acquisition.

At AUD 0.77, the stock is now trading at the higher end of its 52-week range (AUD 0.225 – 0.780), but valuation metrics still imply headroom if CT:VQ adoption accelerates across U.S. hospital networks and global imaging partners. With 388 global deployment sites already using 4DMedical’s SaaS solutions and 194,000+ scans performed in FY2025 alone, the company has shown its ability to convert technological edge into commercial traction.

Should reimbursement pathways solidify and commercial conversions ramp up via channel partners like Philips, Olympus, and Nuance, 4DMedical could enter a flywheel phase—where growth in scans, customer accounts, and referral networks compound quarter-on-quarter. In such a scenario, institutional investors may start pricing 4DMedical not as a speculative medtech moonshot, but as a credible future leader in pulmonary diagnostics, with a defensible moat in functional lung imaging and platform expansion potential across chronic respiratory disease monitoring and AI-driven screening.

In short, the stock’s sharp rally may be less about hype and more about horizon—the market is beginning to assign platform value to what was once seen as just a promising clinical tool. The road to full adoption still depends on execution, but 4DMedical may be entering its most investable phase yet.